Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan) is a leading manufacturer of cardiocerebral vascular (CV) drugs in the PRC. The Group’s 63 drugs, are distributed via an effective and extensive network of more than 2,500 distributors covering 30 provinces, autonomous regions and municipalities.

Headquartered in Haikou, the Group currently manufactures 20 drugs using its own production facilities at 100%-owned Beijing Sihuan Pharmaceutical Co., Ltd and engages third party contract manufacturers to produce 22 other drugs. Sihuan is also the exclusive distributor of 21 drugs on behalf of unrelated pharmaceutical companies.

CV Drugs account for over 80% of Group revenue, driven by Kelinao, Chuanqing and Anjieli. In fact, Kelinao is the PRC’s best selling peripheral vasolidation drug based on the drug purchases of a sample of 257 hospitals.

The Group is led by an experienced management team headed by Executive Chairman and Chief Executive Offi cer Dr Che Fengsheng who holds a Master of Medicine (Neurology) and an Executive Master of Business Administration. Co-founder Dr Guo Weicheng is Sihuan’s Executive Deputy Chairman and holds a Master of Medicine (General Surgery). Besides their practical medical/surgery background, both Dr Che and Dr Guo together have over 15 years of experience in the sales and marketing of pharmaceutical products and management of pharmaceutical companies.

Sihuan’s R&D emphasis helps drive its product development pipeline and the Group currently has over 70 products at various stages of development and fi led more than 300 patent applications for its chemical compound structure. The 120-member strong in-house R&D team in Hainan, Beijing and Shandong, collaborates with renowned third party research institutions, academic bodies and pharmaceutical research companies in the PRC.

Sihuan was listed on the Mainboard of the Singapore Exchange Securities Trading Limited on 23 March 2007.